Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303017 · ClinicalTrials.gov registry record · NA
Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study
A NA study, sponsored by Primus Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT00303017: Completed NA study, sponsored by Primus Pharmaceuticals.
NCT00303017 is a NA study that has completed, run by Primus Pharmaceuticals. The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00303017, a NA study, has completed, sponsored by Primus Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
safety, efficacy and acceptability of Flavocoxid
Interventions
- DRUG Naproxen
- DIETARY_SUPPLEMENT flavocoxid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-09 |
| Phase | NA |
What the finished NCT00303017 record still lists
NCT00303017 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Naproxen is the first listed.
NCT00303017 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00303017 about?
NCT00303017 is a clinical study titled "Safety, Efficacy and Acceptability of Flavocoxid (Limbrel)A Pilot Study". safety, efficacy and acceptability of Flavocoxid
What is the current status of trial NCT00303017?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2006-03. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00303017?
The interventions under investigation include: Naproxen (DRUG), flavocoxid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00303017?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00303017's enrollment target sits among peer trials
60 1164th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia